We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$60.5 after a previous close of US$60.63. During the day the price has varied from a low of USD60.17 to a high of USD61.1. The latest price was USD60.23 (25 minute delay). Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Bristol-Myers Squibb Company
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Bristol-Myers Squibb Company. Find the share by name or ticker symbol: BMY. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bristol-Myers Squibb Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$60.63, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Bristol-Myers Squibb Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Bristol-Myers Squibb Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Bristol-Myers Squibb Company key stats
- Compare share trading platforms
- Is Bristol-Myers Squibb Company stock a buy or sell?
- Bristol-Myers Squibb Company performance over time
- Can I short Bristol-Myers Squibb Company shares?
- Is Bristol-Myers Squibb Company suitable for ethical investing?
- Are Bristol-Myers Squibb Company shares over-valued?
- Bristol-Myers Squibb Company's financials
- How volatile are Bristol-Myers Squibb Company shares?
- Does Bristol-Myers Squibb Company pay a dividend?
- Have Bristol-Myers Squibb Company shares ever split?
- Other common questions
Bristol-Myers Squibb Company stock price (NYSE:BMY)Use our graph to track the performance of BMY stocks over time.
Bristol-Myers Squibb Company shares at a glance
|52-week range||US$55.0111 - US$69.1862|
|50-day moving average||US$61.3283|
|200-day moving average||US$64.9274|
|Dividend yield||US$1.92 (3.33%)|
|Earnings per share (TTM)||US$-2.264|
Where to buy Bristol-Myers Squibb Company stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Bristol-Myers Squibb Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Bristol-Myers Squibb Company shares?Before you consider Bristol-Myers Squibb Company, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Bristol-Myers Squibb Company price performance over time
|1 week (2021-10-06)||1.76%|
|1 month (2021-09-16)||-1.63%|
|3 months (2021-07-16)||-10.51%|
|6 months (2021-04-16)||-7.99%|
|1 year (2020-10-16)||-1.65%|
|2 years (2019-10-17)||14.90%|
|3 years (2018-10-17)||2.26%|
|5 years (2016-10-17)||22.07%|
Stocks similar to Bristol-Myers Squibb Company
Is Bristol-Myers Squibb Company under- or over-valued?
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's PEG ratio
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 13.6713. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$18.8 billion (£13.7 billion).
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.
Bristol-Myers Squibb Company financials
|Revenue TTM||US$44.4 billion|
|Operating margin TTM||18.55%|
|Gross profit TTM||US$34 billion|
|Return on assets TTM||4.31%|
|Return on equity TTM||-11.76%|
|Market capitalisation||US$129.7 billion|
TTM: trailing 12 months
Shorting Bristol-Myers Squibb Company shares
There are currently 19.9 million Bristol-Myers Squibb Company shares held short by investors – that's known as Bristol-Myers Squibb Company's "short interest". This figure is 2% down from 20.3 million last month.
There are a few different ways that this level of interest in shorting Bristol-Myers Squibb Company shares can be evaluated.
Bristol-Myers Squibb Company's "short interest ratio" (SIR)
Bristol-Myers Squibb Company's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb Company shares currently shorted divided by the average quantity of Bristol-Myers Squibb Company shares traded daily (recently around 10.2 million). Bristol-Myers Squibb Company's SIR currently stands at 1.96. In other words for every 100,000 Bristol-Myers Squibb Company shares traded daily on the market, roughly 1960 shares are currently held short.
However Bristol-Myers Squibb Company's short interest can also be evaluated against the total number of Bristol-Myers Squibb Company shares, or, against the total number of tradable Bristol-Myers Squibb Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb Company shares in existence, roughly 10 shares are currently held short) or 0.0091% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb Company shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb Company.
Find out more about how you can short Bristol-Myers Squibb Company stock.
Bristol-Myers Squibb Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol-Myers Squibb Company's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol-Myers Squibb Company's environmental score
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's social score
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb Company's governance score
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.16|
|Total ESG percentile||52.58|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Bristol-Myers Squibb Company share dividends
Dividend payout ratio: 28.99% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 28.99% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.4% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.4% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $1.92 per share.
While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 31 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Have Bristol-Myers Squibb Company's shares ever split?
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Bristol-Myers Squibb Company share price volatility
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$55.0111 up to US$69.1862. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.6254. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company in the news
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
APPH, BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
Frequently asked questions
More guides on Finder
Why is the a2 Milk (A2M) share price on a high?
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Why has the Bank of Queensland (BOQ) share price stumbled?
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
How to invest in the Tissue Repair IPO
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
How to buy Illuvium (ILV) in Australia
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
What is weighing down the Westpac share price today?
Westpac shares are up 43% over the past 12 months.
16 stocks to watch following Sydney’s “freedom day”
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Why is the IAG share price on a high today?
Shares in the insurer are up just 10% in the last 12 months.
How to invest in the Nimy Resources IPO
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
Why the EML Payments share price is plunging today
The payment services company’s shares are up 16% in the last year.
How to invest in the Parabellum Resources IPO
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
Ask an Expert